Tipelukast (DrugBank: Tipelukast)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
85 | 特発性間質性肺炎 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02503657 (ClinicalTrials.gov) | March 2016 | 14/7/2015 | Safety and Tolerability Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | A Randomized, Placebo-Controlled, Double-Blind Six Month Study Followed by an Open-Label Extension Phase to Evaluate the Efficacy, Safety and Tolerability of MN-001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis;IPF | Drug: tipelukast;Drug: Placebo | MediciNova | NULL | Active, not recruiting | 21 Years | 80 Years | All | 15 | Phase 2 | United States |